Alpha Thalassemia Epidemiology Forecast 2025-2034

Alpha thalassemia is an inherited blood disorder that results in the impaired production of the hemoglobin molecule. It occurs when 1 or more of the 4 alpha-globin genes are damaged or missing. Around 5% of the global population carries an alpha-thalassemia variant, with the prevalence highest among individuals of Laotian and Cambodian descent, and is also prevalent among African, Chinese, Vietnamese, Filipino, Mediterranean, Thai, and Middle Eastern populations.

Alpha Thalassemia Epidemiology Forecast Report Coverage

The “Alpha Thalassemia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of alpha thalassemia. It projects the future incidence and prevalence rates of alpha thalassemia across various populations. The study covers age and type as major determinants of the alpha thalassemia-affected population. The report highlights patterns in the prevalence of alpha thalassemia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of alpha thalassemia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Alpha Thalassemia: Disease Overview

Alpha thalassemia is an inherited anemia characterized by reduced production of alpha globin which is a building block of hemoglobin. The blood disorder occurs when one or more of the 4 alpha-globin genes are either missing or damaged. There are four types of alpha thalassemia: alpha thalassemia silent carrier (one gene is missing or damaged), alpha thalassemia carrier (two genes are missing, hemoglobin H disease (three genes are missing), and alpha thalassemia major (all 4 genes are missing). Common symptoms include abnormal bleeding, fatigue, fever, weakness, shortness of breath, and headache, among others.

Alpha Thalassemia: Treatment Overview

Treatment for alpha thalassemia varies depending on the type of alpha thalassemia, the patient's age and general health, and the severity of symptoms. For children and adults with alpha thalassemia major, regular blood transfusions are required to treat and prevent anemia. Chelation therapy is also used to remove excess iron from the body. On the other hand, patients with hemoglobin H disease are typically given folic acid supplements or blood transfusions if hemoglobin levels drop suddenly.

Epidemiology

The alpha thalassemia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for alpha thalassemia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for alpha thalassemia and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Alpha thalassemia is a highly prevalent globin gene disorder in all tropical and subtropical regions, affecting approximately 1 in 10,000 people, particularly within the African equatorial belt. However, intermediate and severe forms of alpha thalassemia are reported to be very rare in North America and Northern Europe, with an incidence of about 1 in 1,000,000 people.
• According to a 2024 review, thalassemia holds a substantial disease burden globally, with around 5% to 20% of the population worldwide having one or more alpha thalassemia mutations.
• As per a North American TCRN study, around 59% of alpha thalassemia patients have a single alpha-globin gene, 8% carry no alpha-globin genes, and approximately 33% show gene deletions along with structural mutations.
• Studies show that alpha thalassemia affects both men and women equally.

Country-wise Alpha Thalassemia Epidemiology

The alpha thalassemia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of alpha thalassemia varies significantly between countries due to several factors including genetic predisposition, patterns of migration, screening and awareness programs, the status of healthcare infrastructure, and environmental factors, among others. Studies reveal that the frequency of alpha thalassemia is low among Whites. On the other hand, around 15% of American Blacks are reported to be silent carriers of this inherited blood disorder and approximately 3% of them have alpha thalassemia trait.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of alpha thalassemia based on several factors.
• Alpha Thalassemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of alpha thalassemia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of alpha thalassemia epidemiology in the 8 major markets?
• What will be the total number of patients with alpha thalassemia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of alpha thalassemia in the 8 major markets in the historical period?
• Which country will have the highest number of alpha thalassemia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of alpha thalassemia during the forecast period of 2025-2034?
• What are the currently available treatments for alpha thalassemia?
• What are the disease risks, signs, symptoms, and unmet needs of alpha thalassemia?

This product will be delivered within 3-5 business days.